Zuellig Pharma Announces Agreement with Regeneron to Introduce Libtayo®
Wednesday, August 28, 2024
Zuellig Pharma has entered into an exclusive distribution agreement with Regeneron Ireland DAC, a subsidiary of Regeneron Pharmaceuticals, Inc.
Libtayo® was developed using Regeneron's VelocImmune® technology and has received regulatory approval in over 24 countries for various medical conditions. In Taiwan, it is approved for monotherapy in advanced NSCLC.
This partnership will see Zuellig Pharma launch and commercialise Libtayo® (cemiplimab), a fully human monoclonal antibody that targets the PD-1 receptor on T cells, in South Korea and Taiwan.
Regeneron is a leading biotechnology firm known for developing and marketing life-changing medicines for serious illnesses.
In South Korea, Libtayo® is already approved as a first-line monotherapy for advanced non-small cell lung cancer (NSCLC), as well as for treating metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) and recurrent or metastatic cervical cancer.
Zuellig Pharma are eager to bring Libtayo® to patients in South Korea and Taiwan. Extensive experience in Asia’s biopharma sector enables us to deliver innovative therapies to the region.
This marks an important step in the mission to enhance healthcare access and improve patient outcomes, particularly in the growing field of oncology.
Source: zuelligpharma.com
